N. Acar, M. Çakır, Y. B. Ünver, Z. Kapran, T. Altan, Z. Bayraktar, E. Y. Pınarcı, I. Perente, M. Dogan


To evaluate the efficacy of intravitreal triamcinolone acetonide (IVTA) injection for the treatment of macular edema (ME) due to branch retinal vein occlusion (BRVO) by OCT.


In this prospective study, a total 42 eyes of 42 patients with BRVO in which visual acuity is ≤ 0.5 Snellen lines with ME were included in this study. 4 mg/0.1 ml IVTA injection was performed in all patients. The central macular thickness (CMT) were recorded preoperatively and postoperatively on the 3rd day, 1st week, 1st, 3rd months. Visual acuities (VA) and intraocular pressures (IOP) were recorded.


The mean age of 12 female, 30 male patients was 65.7±11,4 (39-83) years. The mean follow-up time was 12,8±8,3 weeks. Preoperatively mean CMT was 430±140μ. Postoperatively CMT was 264±119 on the 3rd day, 230±80 on the 1st week, 223±67 on the 1st month, 339±152 on the 3rd month. The decrease in ME was significant during all follow-up times (p<0.05 at all times). The mean VA was 0.16±0.13 Snellen lines before IVTA, 0.20±0.18 on the 1st week, 0.23±0.18 on the 1st month and 0.24±0.13 on the 3rd month. The increase in VA on the 1st and 3rd months were statistically significant (p<0,05 at all times). The IOP rise over 25 mmHg detected in 7 cases (16.6%) after injection was medically controlled. Endophthalmitis did not develop in any of the patients.


IVTA in the treatment of ME due to BRVO leads to significant decrease in CMT starting from postinjection 3 days and being stable during 3 months follow-up; whereas, increase in VA was significant after 1st month and was stable for 3 months follow-up.

Take-home message:

The decrease in CMT by IVTA in ME due to BRVO is prominent during 3 days – 3 months time, but increase in VA starts in the 1st month.